Acute respiratory distress syndrome (ARDS)
Supplements studied for acute respiratory distress syndrome (ARDS).
Overview
Three supplements are indexed for acute respiratory distress syndrome (ARDS) across 11 studies, all with low to medium-low ratings.
Inositol (DEX Score 52; low effect size, high evidence, medium trust) was once considered for premature infants, but newer high-quality research found no benefit and possible increased risks of death or serious complications; it is not recommended for infants at risk of ARDS. Gamma-Linolenic Acid (DEX Score 52; low effect size, high evidence, medium trust) has only been studied in combination formulas for severe lung disease, with no clear improvements in survival, ventilator time, or ICU stay.
N-Acetyl Cysteine (NAC) (DEX Score 48; low effect size, medium evidence, medium trust) given intravenously shows mixed results—some studies suggest possible benefit for breathing and survival, others find none—and oral NAC has not been studied for ARDS. Genetic differences may influence response. See the heatmap and evidence reviews below for full trial detail.
Effect graph
Subscribe to access all content
Interactive visualisations of ranked conditions and clinical benefit with purchase guidance.
Already a subscriber? Sign in
Relevant supplements heatmap
Relevant supplements sorted by DEX Score.
Subscribe to access all content
See effect size, evidence strength, and trust at a glance for every condition.
Already a subscriber? Sign in
SupplementDEX Database
3 supplements for rated at least stars. All purchase bands. No minimum star filter.
Subscribe to access all content
Read this and 2,600+ other evidence reviews on our practitioner plan.
Already a subscriber? Sign in
Evidence visualised
Subscribe to view condition evidence
Visual summaries of supplement evidence ranked by condition.
Already a subscriber? Sign in